Combined Screening + Hb Pathies (CLIA)

Combined Screening + Hb Pathies (CLIA)

Overview
The Combined Screening + Hb Pathies (CLIA) test is a comprehensive prenatal screening panel designed to assess the risk of common chromosomal abnormalities along with screening for inherited hemoglobin disorders (hemoglobinopathies). It helps identify pregnancies that may require further diagnostic evaluation and supports early clinical decision-making.

Why is this test done?

• Screens for the risk of major fetal chromosomal abnormalities.
• Detects carrier status for common hemoglobinopathies.
• Supports early prenatal risk assessment.
• Helps guide genetic counseling and further confirmatory testing when indicated.

Who should consider this test?

• Pregnant women during the first trimester (as recommended by their healthcare provider).
• Couples with a family history of hemoglobin disorders.
• Individuals belonging to populations with a higher prevalence of thalassemia or sickle cell disease.
• Women seeking comprehensive prenatal screening.

Sample Required

• Maternal blood sample (Serum/Whole Blood as per laboratory protocol).

Benefits

• Early identification of pregnancies at increased genetic risk.
• Simultaneous assessment of chromosomal and hemoglobinopathy risks.
• Facilitates timely counseling and informed pregnancy management.
• Non-invasive and safe for both mother and fetus.

Preparation

• No special fasting or preparation is generally required.
• Clinical details such as maternal age, gestational age, weight, and ultrasound findings (if applicable) should be provided for accurate interpretation.

Note
This is a screening test, not a diagnostic test. A high-risk result does not confirm a fetal condition, and additional diagnostic testing may be recommended by the treating physician.

Book your Combined Screening + Hb Pathies (CLIA) test with Advanced BioCare Laboratories for accurate, reliable, and timely prenatal screening.